EAN 2026: Regeneron highlights disease control potential of cemdisiran in gMG

Regeneron's Phase III trial investigated cemdisiran and pozelimab as both monotherapies and in combination in gMG. Regeneron's Phase III trial investigated cemdisiran and pozelimab as both monotherapies and in combination in gMG. The FDA is currently reviewing a New Drug Application (NDA) for cemdisiran as a treatment for adults with generalized myasthenia gravis (gMG). Credit: lev radin / Shutterstock.com Regeneron’s Phase III generalised myasthenia gravis (gMG) trial shows high disease control potential of cemdisiran. The Phase III NIMBLE study (NCT05070858) evaluated cemdisiran and pozelimab in patients with gMG. LOA and PTSR Model Monoclonal Antibody Conjugate 3 To Target Egfr...…

Source: Clinical Trials Arena